Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion

← catalyst calendar

NCT07599007 · readout in 498 d

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase

—

Status

Not yet recruiting

Study type

Observational

Enrollment

10estimated

Sites

Country

South Korea

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-05-24

estimated

When the study began enrolling

Primary completion

2027-12-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-01-31

estimated

The whole study's end, after follow-up

First posted

2026-05-20

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-20

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Non-Small Cell Lung Cancer

Intervention

Drug: Repotrectinib

Primary outcome

what the primary-completion date above is the date OF

Number of participants experiencing adverse events

measured Up to 12 months

Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed